Mon.Dec 23, 2024

article thumbnail

Trade & Channel Strategies 2024: Navigating Industry Challenges

Pharmaceutical Commerce

Jon Hamrick, partner, Curatio Scientia Advisors, discusses upcoming industry challenges at this year's Trade & Channel Strategies Conference in Philadelphia.

52
article thumbnail

FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea

Pharmaceutical Technology

Lillys Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Your Sniffles Could Be a Sign of The Fungi Hidden in Your Nose

AuroBlog - Aurous Healthcare Clinical Trials blog

(Runstudio/Photodisc/Getty Images) If you find yourself sniffling at the merest hint of an irritant, you likely have a different set of microbes calling your nostrils home than everyone else. An international team of researchers has found a unique assortment of fungi up the noses of people who suffer from hayfever and asthma.

Research 238
article thumbnail

Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA

Pharmaceutical Technology

Pfizer has gained accelerated approval from the US FDA for BRAFTOVI in conjunction with cetuximab and mFOLFOX6 for treating mCRC.

162
162
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Top 5 Things to Know Before Joining a Clinical Trial

Pharma Mirror

Have you ever wondered how life-saving treatments for cancer, Alzheimers, or chronic diseases come to life? Clinical trials are the foundation of medical innovation, paving the way for groundbreaking therapies. Yet for many, the idea of joining a trial can feel intimidating or unclear. Experts are here to demystify the clinical trial process, with Dr.

article thumbnail

Eli Lilly’s UK life sciences investment ‘a pivotal moment’, says analyst

Pharmaceutical Technology

GlobalData analysis sees Lilly's investment in UK life sciences as an opportunity to drive economic growth whilst improving public health.

More Trending

article thumbnail

Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings

Pharmaceutical Technology

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.

147
147
article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

The FDA approved Novo Nordisk's tissue factor pathway inhibitor (TFPI) antagonist concizumab as a once-a-day treatment to prevent or curb the frequency of bleeding episodes in patients ages 12 and older who have hemophilia A or B with inhibitors. The green light follows a rejection in 2023 and a trial pause over safety concerns several years before that.

article thumbnail

Investors optimistic about continued biotech and medtech IPO resurgence in 2025

Pharmaceutical Technology

Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.

147
147
article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

Bristol Myers Squibb has reported positive results for two phase 3 trials of Sotyktu in adult patients who have psoriatic arthritis. Without revealing figures, BMS said that the POETYK PsA-1 and POETYK PsA-2 studies achieved their respective primary endpoints, as a significantly greater proportion of patients on Sotyktu achieved at least a 20 percent improvement in symptoms compared to those on placebo at Week 16.

Trials 91
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines

Pharmaceutical Technology

SK bioscience and Sanofi have expanded their agreement to jointly develop pneumococcal conjugate vaccines (PCVs).

Vaccine 147
article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

The FDA has approved Vertexs Alyftrek, a once-daily triple combination for the treatment of cystic fibrosis. But analysts have different views on how the switch from Vertex's twice-daily Trikafta will play out.

69
article thumbnail

International Day of Epidemic Preparedness 2024: Amplifying Global Resilience

XTalks

The International Day of Epidemic Preparedness, observed annually on December 27 , underscores the necessity of global collaboration to address epidemic threats. Proclaimed by the United Nations (UN) in 2020, this day honors lessons from past crises like COVID-19, emphasizing the importance of readiness in safeguarding lives and economies. A recent World Health Organization (WHO) report revealed a troubling decline in health spending , threatening epidemic resilience by weakening critical system

Vaccine 52
article thumbnail

Quality compliance in the digital era

pharmaphorum

Stay updated on the latest Good Manufacturing Practices (GMP) and quality compliance standards in the digital era with our comprehensive guide. Learn how to ensure your products meet regulatory requirements.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Deupirfenidone Could Perform Better Than Standard IPF Therapy

XTalks

A new Phase IIb clinical trial, ELEVATE IPF, has delivered promising results for deupirfenidone ( LYT-100 ), an investigational drug being evaluated to slow lung function decline in patients with idiopathic pulmonary fibrosis (IPF). The trial involved 257 participants and tested two doses of deupirfenidone over 26 weeks, with participants taking the drug three times a day (TID).

article thumbnail

Drug Patent Expirations for the Week of December 22, 2024

Drug Patent Watch

VICTRELIS (boceprevir) Merck sharp dohme Patent: RE43298 Expiration: Dec 22, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.

Drugs 52
article thumbnail

Forecasting the 2025 Healthcare Logistics Space

Pharmaceutical Commerce

How will supply chains in the space continue to develop?

article thumbnail

2025 Clinical Trials Outlook: Six Industry Trends to Expect

Velocity Clinical Research

Rising costs, evolving regulations, and the unstoppable growth of AI are set to shape clinical trials in 2025. How will sites, new tech, promising obesity drugs, and shifting policies affect our industry? Read this article from Paul Evans featured on PharmiWeb: [link] The post 2025 Clinical Trials Outlook: Six Industry Trends to Expect appeared first on Velocity Clinical Research.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Pharma Pulse 12/23/24: Impact of DEA Telehealth Extensions, Big Jump in US Healthcare Spending & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

52
article thumbnail

Fierce Pharma - Untitled Article

Fierce Pharma

For many readers, the topics featured in this years roundup of top stories wont come as much of a surprise. Look no further than our top two stories of the year, and youll see that the GLP-1 craze and Big Pharma layoffs took center stage in 2024.

52
article thumbnail

The Sun Has Started to Set on the Rare Pediatric Disease Priority Review Voucher Program – But It Can Still be Saved

FDA Law Blog

By Mark A. Tobolowsky & Frank J. Sasinowski The Winter Solstice, signifying the shortest day of the year, was Saturday, December 21. Although the earliest sunset of the year was actually in early December, this day also marked another premature sunset the beginning of the end of the rare pediatric disease priority review voucher program. As we blogged recently, the program has had scheduled sunset dates from its very beginning, which have been repeatedly extended.

Drugs 52
article thumbnail

Parliamentary panel asks Centre to augment manpower in CDSCO

AuroBlog - Aurous Healthcare Clinical Trials blog

The Parliamentary Standing Committee on Chemicals and Fertilisers has recommended to the government to assess the actual staffing requirement of the Central Drugs Standard Control Organisation (CDSCO) since the existing posts are insufficient to meet the country’s regulatory requirements.

Drugs 188
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

DDW Highlights: 23 December 2024

Drug Discovery World podcast

The latest episode of the DDW Highlightspodcast is now available to listen to and watch below. DDWs Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we approach the end of 2024, its great to see that investment in drug discovery is still going strong, with an impressive $300 million raised by AI-focused company SandboxAQ and another significant financing by Ottimo Pharma.

Drugs 52